Results: The assay of fluorescent quantitation PCR showed that The expression of PLAG1mRNA in the plasma of patients with hepatocellular

carcinoma was significantly higher than that of liver cirrhosis, healthy control group. ELISA showed that the plasma level of PLAG1 protein in patients with hepatocellular carcinoma was significantly higher than that in healthy control group, liver cirrhosis. Conclusion: PLAG1 in plasma of the patients with hepatocellular carcinoma were at high level, that it play a significant role in the occurrence and development of hepatocellular carcinoma, PLAG1mRNA and PLAG1protein may become a new complementary tumor marker for diagnosis of hepatocellular Doxorubicin carcinoma. Key Word(s): 1. HCC; 2. PLAG1; 3. ELISA; 4. RT-PCR; Presenting Author: TENGHAO ZHENG Additional Authors: YUXIU YANG Corresponding Author: TENGHAO ZHENG, YUXIU YANG Affiliations: Henan Provincial Hospital Objective: MCM6, which have recently emerged as a useful biomarker of cell cycle state, GSI-IX research buy were involved in cell proliferation

and human oncogenesis. Elevated level of MCM6 mRNA and protein was found in several tumor tissues, including hepatocellular carcinoma. This study aims to investigate the levels of cell-free MCM6 mRNA and protein in plasma of HCC patients, cirrhosis patients as well as healthy controls, and evaluate its diagnostic value for HCC. Methods: Blood samples were collected from 61 patients with Hepatocellular Carcinoma, 29 patients with cirrhosis, and 30 healthy volunteers. Circulating mRNAs of MCM6 and NADPH were extracted from plasma and quantified by Real-time PCR. MCM6 protein was detected and quantified by enzyme linked immunosorbent see more assay (ELISA). Results: All

samples showed detectable quantities of cell-free MCM6 and NADPH mRNAs and protein in plasma. NADPH was used as housekeeping gene for normalization. In controls, 3 cases (10%) were positive for MCM6 mRNA, and 9 (31%) were positive in liver cirrhosis patients; of the 61 HCC patients, 40 cases (66%) were positive. These differences were statistically significant (P < 0.01). And the MCM6 mRNA levels in HCC patients were higher than those in liver cirrhosis patients (P < 0.05) and healthy controls (P < 0.01). Tumor size (P < 0.01) pathological stage (P < 0.05) were associated with the presence of MCM6 RNAs in plasma. The plasma MCM6 protein level in HCC patients were higher than those in cirrhosis patients (P < 0.05) and healthy controls (P < 0.05). Conclusion: Our results suggest that levels of cell-free MCM6 mRNA and protein in plasma may be clinically useful as noninvasive diagnostic markers in differentiating HCC patients from cirrhosis patients and normal individuals. Key Word(s): 1. HCC; 2. MCM6; 3. ELISA; 4.